Foscenvivint for HIV/HCV cirrhosis with hemophilia
Part of Blood & lymphatic, Digestive system, Genetic & congenital clinical trials.
This trial tests a drug called foscenvivint for people with hemophilia and liver cirrhosis caused by both HIV and hepatitis C (already treated). The study aims to see if it can help improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia and liver cirrhosis caused by HIV and hepatitis C (HCV) co-infection.
- Your HIV is well-controlled (virus level under 200 copies/mL and CD4 count at least 200).
- You have been cured of hepatitis C for at least 12 months.
- Your cirrhosis is mild to moderate (Child-Pugh class A or B, score 5-9).
- You have a confirmed diagnosis of cirrhosis (by scan or CT).
- You are in good enough health to be up and about (ECOG performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
This trial tests if a drug can lower inflammation in people with HIV who are on effective treatment. It may help reduce the risk of heart disease and other problems related to chronic inflammation.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests if Vosevi (a combination of three antiviral drugs) can clear the hepatitis C virus in people who have already tried standard antiviral treatment but still have the virus. It also compares this to another treatment option.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.